Drug Trial Radar · NCT00541086
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,697
Actual
Start
Mar 2007
Primary completion
Jul 2020
Study completion Jul 2020
Sponsor
- Lead sponsor
- Gruppo Italiano Mammella (GIM)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking use of estrogen by the tumor cells. Anastrozole, letrozole, and exemestane may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether giving tamoxifen followed by anastrozole, letrozole, or exemestane is more effective than giving anastrozole, letrozole, or exemestane alone in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving tamoxifen followed by either anastrozole, letrozole, or exemestane to see how well it works compared to anastrozole, letrozole, or exemestane alone in treating postmenopausal women with hormone-responsive invasive breast cancer that has been completely removed by surgery.
Conditions
- Breast Cancer
Interventions
anastrozoleDrug
1 mg per day, orally
exemestaneDrug
25 mg per day, orally
letrozoleDrug
2.5 mg per day, orally
tamoxifen citrateDrug
20 mg per day, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survivalTime frame: 5 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Federico II University Medical School
Naples, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori
Naples, Italy
Seconda Universita di Napoli
Naples, Italy
Arcispedale S. Maria Nuova
Reggio Emilia, Italy
Istituti Fisioterapici Ospitalieri - Roma
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.